Search Result

Results for "

MDM2/p53

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (28) Autophagy (5) Bcl-2 Family (1) Casein Kinase (3) CDK (2) Deubiquitinase (4) Dihydroorotate Dehydrogenase (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (28) Ferroptosis (1) Fungal (1) HDAC (2) IAP (1) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (91) NF-κB (2) PROTACs (4) Sirtuin (1) β-catenin (2)
By Research Areas:	Cancer (104) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)

104

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-70028

p53 and MDM2 proteins-interaction-inhibitor (racemic)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-161039

MDM2-p53-IN-18	MDM-2/p53	Cancer
MDM2-p53-IN-18 (Compd A-7b) is a *MDM2-p53* interaction inhibitor .

HY-161041

MDM2-p53-IN-20	MDM-2/p53	Cancer
MDM2-p53-IN-20 (Compd B-11j) is a synthetic *MDM2-p53* interaction inhibitor that play an important role in cancer .

HY-161040

MDM2-p53-IN-19	MDM-2/p53	Cancer
MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the *MDM2-p53* interaction with anticancer activity .

HY-151170

MDM2/4-p53-IN-2	MDM-2/p53 Apoptosis	Cancer
MDM2/4-p53-IN-2 (2q) is a potent dual **MDM2/ MDM4 inhibitor and p53 activator with the IC₅₀** values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .

HY-163661

p53-MDM2-IN-5	Apoptosis Autophagy MDM-2/p53	Cancer
p53-MDM2-IN-5 (compound 5a) is a potent *p53-MDM2* inhibitor. p53-MDM2-IN-5 induces apoptosis, autophagy and DNA damage. p53-MDM2-IN-5 induces cell cycle arrest at S and G2/M phases. p53-MDM2-IN-5 shows anti-tumor activity .

HY-151172

MDM2-p53-IN-15	MDM-2/p53 Apoptosis	Cancer
MDM2-p53-IN-15 is a *MDM2-p53* inhibitor with an IC₅₀ value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .

HY-168606A

p53-MDM2-IN-7 hydrochloride	MDM-2/p53	Cancer
p53-MDM2-IN-7 (compound 6d) (hydrochloride) is a *p53-MDM2* inhibitor. p53-MDM2-IN-7 has an IC₅₀ value of 8.13 μM against A549 cells. p53-MDM2-IN-7 can be used in anti-cancer research .

HY-162927

p53-MDM2-IN-6	MDM-2/p53 Apoptosis	Cancer
p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent *p53-MDM2* inhibitor with an IC₅₀ value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC₅₀ value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-116052

p53-MDM2-IN-2	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-2 (Compound 5q) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .

HY-121893

p53-MDM2-IN-3	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-3 (Compound 5s) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-151171

MDM2/4-p53-IN-3	MDM-2/p53	Cancer
MDM2/4-p53-IN-3 is a *MDM2/4-p53* protein-protein interactions (PPIs) inhibitor (IC₅₀s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .

HY-151169

MDM2/4-p53-IN-1	MDM-2/p53	Cancer
MDM2/4-p53-IN-1 is a potent *MDM2-p53* and *MDM4-p53* inhibitor with IC₅₀ values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .

HY-14967

NSC 66811	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-150620

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent *MDM2-p53* interaction inhibitor .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-134823

MD-222	MDM-2/p53 PROTACs E1/E2/E3 Enzyme	Cancer
MD-222 is the first-in-class highly potent PROTAC degrader of *MDM2. MD-222 consists of ligands for Cereblon* and *MDM2. MD-222 induces rapid degradation of the MDM2* protein and activation of wild-type p53 in cells. MD-222 has anticancer effects ^[2].

HY-162247

MDM2-IN-26	MDM-2/p53	Cancer
MDM2-IN-26 (compound A3) is an *MDM2* inhibitor that can activate the tumor suppressor function of *p53* by blocking the interaction between MDM2 and p53 (MDM2 is the main negative regulator of p53). MDM2-IN-26 can be used for cancer research .

HY-162432

MDM2-IN-27	MDM-2/p53	Cancer
MDM2-IN-27 targets *MDM2* protein (K_i = 0.4 nM). MDM2-IN-27 activates the anti-tumor activity of p53 and induces apoptosis by blocking the negative regulation of p53 by MDM2 .

HY-107466

WK298	MDM-2/p53	Cancer
WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .

HY-153215

MEL24	Others	Cancer
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies .

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-149250

MDMX/MDM2-IN-2	MDM-2/p53 Apoptosis	Cancer
MDMX/MDM2-IN-2 is a potent *p53-MDM2/MDMX* dual inhibitors with K_is of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .

HY-15335

Nutlin-3b 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a *p53/MDM2* inhibitor with an IC₅₀ of 13.6 μM. Nutlin-3b is 150 times less potent in binding to *MDM2* than Nutlin-3a (HY-10029). Nutlin-3b is promising for research of cancers ^[2] .

HY-130684

MDM2-IN-1	MDM-2/p53	Cancer
MDM2-IN-1 (Compound 30) is a synthetic **MDM2-p53 interaction (MDM2)** inhibitor and contains the trans (D-)configuration .

HY-15676

Idasanutlin 35+ Cited Publications RG7388	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-123544

RDR03871	MDM-2/p53	Cancer
RDR03871 (compound 2) is a potent dual *MDM2/MDM4* inhibitor with IC₅₀ values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-101518

Alrizomadlin APG-115; AA-115	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Alrizomadlin (APG-115) is an orally active *MDM2* protein inhibitor binding to MDM2 protein with IC₅₀ and K_i values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner ^[2] .

HY-155974

MeOIstPyrd	MDM-2/p53	Cancer
MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates *p53, and increases the half-life of p53* and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .

HY-18052

AM-8553	MDM-2/p53	Cancer
AM-8553 is a *MDM2/p53* inhibitor (K_D: 0.4 nM for MDM2). AM-8553 has anti-tumor activity

HY-50696

Nutlin-3 20+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-120086

RO-5963	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RO-5963 is a dual *p53-MDM2* and *p53-MDMX* inhibitor with IC₅₀s of ~17 nM and ~24 nM, respectively .

HY-169327

MD-265	PROTACs MDM-2/p53	Cancer
MD-265 is a PROTAC degrader that can break down *MDM2, leading to activation of p53* in cancer cells carrying wild-type p53. MD-265 achieves complete tumor regression and improves long-term survival of mice with leukemia. (Pink: MI-1063 (HY-133754); Black: linker; Blue: Lenalidomide (HY-A0003) .

HY-12580

RO5353	MDM-2/p53	Cancer
RO5353 is an orally active inhibitor for *p53-MDM2* with an IC₅₀ of 7 nM for MDM2. RO5353 inhibits the proliferation of wild-type p53 cancer cells with an average IC₅₀ of 7 nM. RO5353 exhibits antitumor efficacy and good pharmacokinetic characteristics in mice .

HY-144105

NSC405640	MDM-2/p53	Cancer
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

HY-169240

MX69-102	MDM-2/p53	Cancer
MX69-102 (compound MX69-102) is an *MDM-2/p53* inhibitor, inducing *MDM2* degradation, resulting in *p53* activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .

HY-10959

RG7112 15+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-12296

Navtemadlin 15+ Cited Publications AMG 232; KRT-232	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of *p53-MDM2* interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM ^[2].

HY-124739

HBX 28258	Deubiquitinase	Cancer
HBX 28258 is a selective USP7 inhibitor, with an IC₅₀ of 22.6 μM. HBX 28258 can covalently binds to Cys223 located in the catalytic core of USP7, inhibits its deubiquitinating activity, promotes MDM2 protein degradation, and activates p53 .

HY-15676A

Idasanutlin (enantiomer) RG7388 (enantiomer)	MDM-2/p53 Drug Isomer Apoptosis	Cancer
Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-123950

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts *Mdm2-MdmX* interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces *p53* accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

HY-101266A

Milademetan tosylate DS-3032 tosylate	MDM-2/p53	Cancer
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for *MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis* Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC) .

HY-18658

Siremadlin 5+ Cited Publications NVP-HDM201; HDM201	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific *p53-MDM2* interaction inhibitor.

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library

2,554 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 2,554 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L109

Protein-protein Interaction Inhibitor Library

651 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 651 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-P3509A

PNC-28 acetate	Peptides	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research ^[2].

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-P1755

p53 (17-26)	MDM-2/p53	Cancer
p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain .

HY-P3509

PNC-28	Peptides	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research ^[2].

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701593

	MDM2 Protein, Human MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human is the recombinant human-derived MDM2 protein, expressed by E. coli , with tag free. The total length of MDM2 Protein, Human is 95 a.a., with molecular weight of 11.1 kDa.

HY-P701594

	MDM2 Protein, Human (His) MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human (His) is the recombinant human-derived MDM2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of MDM2 Protein, Human (His) is 95 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia ^[2].

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM[1][2].

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity ^[2] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83705

	MDM2 Antibody (YA3442) ACTFS antibody; Double minute 2 protein antibody; E3 ubiquitin-protein ligase MDM2 antibody; Hdm 2 antibody; Hdm2 antibody; HDMX antibody; MDM 2 antibody; MDM2 antibody; MDM2 oncogene E3 ubiquitin protein ligase antibody; MDM2 p53 E3 ubiquitin protein ligase homolog antibody; MDM2 transformed 3T3 cell double minute 2 p53 binding protein (mouse) binding protein 104kDa antibody; MDM2_HUMAN antibody; MDM2BP antibody; Mouse Double Minute 2 antibody; MTBP antibody; Murine Double Minute Chromosome 2 antibody; Oncoprotein MDM2 antibody; p53 Binding Protein MDM2 antibody; p53-binding protein MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody	WB, IHC-P, ICC/IF	Human, Monkey
	MDM2 Antibody (YA3442) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA3442), targeting MDM2, with a predicted molecular weight of 55 kDa (observed band size: 90 kDa). MDM2 Antibody (YA3442) can be used for WB, ICC/IF, IHC-P experiment in human, monkey background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: